Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration-Reference-Cited by-同舟云学术

Durability of every-8-week aflibercept maintenance therapy in treatment-experienced neovascular age-related macular degeneration

Published:2019-02-26 Issue:4 Volume:257 Page:741-748
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Dans Kunny C.,Freeman Sarah R.,Lin Tiezhu,Meshi Amit,Olivas Sergio,Cheng Lingyun,Amador-Patarroyo Manuel J.,Freeman William R.

Funder

University of California, San Diego (US) Vision Research Center Core Grant

Research to Prevent Blindness

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

http://link.springer.com/article/10.1007/s00417-018-04232-8/fulltext.html

Reference20 articles.

1. Regeneron Pharmaceuticals (2011) Highlights of prescribing information. https://www.regeneron.com/sites/default/files/EYLEA_FPI.pdf . Accessed 01 Feb 2017

2. You Q, Meshi A, Ramkumar HL et al (2017) Aflibercept for recalcitrant neovascular age-related macular degeneration. Retina 38(6):1156–1165. https://doi.org/10.1097/IAE.0000000000001726

3. Arcinue CA, Ma F, Barteselli G, Sharpsten L et al (2015) One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol 159(3):426–436. https://doi.org/10.1016/j.ajo.2014.11.022

4. Muftuoglu IK, Arcinue CA, Tsai FF et al (2016) Long-term results of pro re nata regimen of aflibercept treatment in persistent neovascular age-related macular degeneration. Am J Ophthalmol 167:1–9. https://doi.org/10.1016/j.ajo.2016.03.038

5. Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. Ophthalmology 119(7):1388–1398. https://doi.org/10.1016/j.ophtha.2012.03.053.Ranibizumab

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Intravitreal Steroid and Anti-VEGF Therapy for Monotherapy-Resistant Chronic Wet Age-Related Macular Degeneration;Ophthalmic Surgery, Lasers and Imaging Retina;2024-08

2. Short-Term Real-World Outcomes of Intensive Aflibercept Injection for Refractory Neovascular Age-Related Macular Degeneration;Journal of Clinical Medicine;2024-06-15

3. Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand;Journal of Ocular Pharmacology and Therapeutics;2023-12-20

4. Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases;Investigative Opthalmology & Visual Science;2023-05-30

5. Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration;Journal of Clinical Medicine;2022-03-11